Hepatitis B Virus - Chronic Active

1

Review clinical trials related to Hepatitis B Virus - Chronic Active. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women

Pregnant women with HBeAg-positive viral hepatitis b or high viral load will receive Tenofovir disoproxil fumarate (TDF) from the 28th week of amenorrhoea until 6 weeks after delivery. Their newborns will receive the hepatitis B vaccine, starting with one dose at birth and followed by three booster doses, according to the Expanded Programme on Immunisation. The investigators hypothesise that a short course of TDF could greatly reduce the risk of HBV MTCT in pregnant women at high risk of MTCT (HBeAg positive or with high viral load).

Participants needed: 150
Trial details
Phase: Phase 4Age: 16+Biological sex: FemaleType: InterventionalSponsor: ANRS, Emerging Infectious DiseasesUpdated: Jun 29, 2026Locations: 1
Eligibility criteria

Pregnant women with a term of less than 24 weeks of amenorrhea; [+4]

HIV co-infection; [+4]